This activation of SF by TGF-β1 and LM-111 works in the absence of TNF-α and IL-1β does not depend on NFκB signalling, and thus may contribute to tissue destruction in the joints of RA patients, even after administration of pharmaceuticals controlling bioactive TNF-α or IL-1β. The gene discussed is IL1B; the disease is rheumatoid arthritis.